Wave Life Sciences/WVE

$5.80

-3.33%
-
1D1W1MYTD1YMAX

About Wave Life Sciences

Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).

Ticker

WVE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Paul Bolno

Employees

266

Headquarters

Null, Singapore

WVE Metrics

BasicAdvanced
$709.25M
Market cap
-
P/E ratio
-$0.54
EPS
-1.06
Beta
-
Dividend rate
$709.25M
-1.05535
$7.67
$3.15
884.75K
1.262
-27.3%
-70.41%
6.26
17.44
14.93
3,005.1%
74.61%
78.04%

What the Analysts think about WVE

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
124.14% upside
High $19.00
Low $5.00
$5.80
Current price
$13.00
Average price target

WVE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-55.86% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$29M
-41.06%
Net income
$-16.2M
-325%
Profit margin
-55.86%
-481.82%

WVE Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 33.82%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.27
-$0.20
$0.07
-$0.15
-
Expected
-$0.04
-$0.33
-$0.18
-$0.23
-$0.21
Surprise
575%
-39.66%
-139.25%
-33.82%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Wave Life Sciences stock?

Wave Life Sciences (WVE) has a market cap of $709.25M as of April 15, 2024.

What is the P/E ratio for Wave Life Sciences stock?

The price to earnings (P/E) ratio for Wave Life Sciences (WVE) stock is 0 as of April 15, 2024.

Does Wave Life Sciences stock pay dividends?

No, Wave Life Sciences (WVE) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Wave Life Sciences dividend payment date?

Wave Life Sciences (WVE) stock does not pay dividends to its shareholders.

What is the beta indicator for Wave Life Sciences?

Wave Life Sciences (WVE) has a beta rating of -1.06. This means that it has an inverse relation to market volatility.

What is the Wave Life Sciences stock price target?

The target price for Wave Life Sciences (WVE) stock is $13, which is 124.14% above the current price of $5.8. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Wave Life Sciences stock

Buy or sell Wave Life Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing